Akelos Inc.
New York, NY
- UEI
- JLTKFBSDPLR4
- CAGE
- 8CL63
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 215 E 68th St #26B, New York, NY 10065, USA
- Website
- akelosinc.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Optimization of an HCN1-selective inverse agonist for the treatment of peripheral neuropathic pain | National Institute of Neurological Disorders and Stroke (NIH) | $1,747,045 |
Quick answers
Is Akelos Inc. registered in SAM.gov?
Yes. Akelos Inc.'s SAM.gov registration is active through March 27, 2027.
What is Akelos Inc.'s most recent federal award?
Akelos Inc.'s most recent federal grant award is Optimization of an HCN1-selective inverse agonist for the treatment of peripheral neuropathic pain (R42NS129370), from National Institute of Neurological Disorders and Stroke (NIH), on September 23, 2022.
On GovTribe
See Akelos Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors